It has discontinued lead Phase IIb maturation inhibitor BMS-955176, which it bought from BMS, and COPD candidate losmapimod.
Biogen is aggressively pursuing neurodegenerative diseases, such as spinal muscular atrophy and Alzheimer’s disease.
Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Learn how this…
Genomics Medicine Ireland has raised $40 million in a Series A round to create a genomic R&D program based in Dublin.
An IPO for Ra Pharmaceuticals has priced raising $92 million, while another for Myovant Sciences has commitments from Pfizer and BB Biotech.
Verona Pharma has secured funding for a Phase IIa trial of its PDE3/PDE4 inhibitor RPL554 in cystic fibrosis patients.
After FDA inspections turned up “limited to no reporting” of injuries or deaths stemming from the use of medical devices at 17 hospitals, the agency is setting…
Teva and IBM have formed a three-year, Watson-enabled drug repurposing collaboration
A new study has shown promise in mice for an experimental drug for Alzheimer's disease.
Using whole-exome sequencing, a previously unannotated gene variant involved in immune cell development has recently been uncovered.
New York University researchers seeking to prove how a protein protects asthmatics from lung damage may have found a new treatment for Gaucher disease, in…